Recently, LSPediA traveled to Long Island, NY to meet with Genetco’s VP of Operations, Bill Carney for a Customer Care Meeting. These meetings are standard care for all LSPediA customers…
Learn More
Israel is familiar with the challenges that an unfit DSCSA solution can bring to his clients. He has seen the frustration his customers. In 2020, his customers came to him…
1 DSCSA and Real-World Challenges: Supply Chain Disruptions The challenging task of distributing generic pharmaceuticals to a huge network of hospitals, pharmacies, prisons and more in 48 states in the…
Faced with the challenges of serialization and complex operational issues surrounding the Drug Supply Chain Security Act (DSCSA), manufacturers, wholesalers, and dispensers choose LSPediA solution to make, move, protect their…
You’re all-in on DSCSA in 2020—and so are we. Your business is going to have a busy 2020: meeting deadlines, complying with requirements, changing business processes—all while meeting customer needs as well. We want to help you make it all successful.
In April of 2019, LSPediA was selected by the FDA to participate in the FDA DSCSA Pilot Project Program, focusing on utilizing LSPediA’s OneScan Solution for Verification, Notification, and Interoperability….
In addition to our wonderful customers, we at LSPediA are all thankful for drug safety progress and innovations. The DSCSA is changing the way drugs are tracked and delivered in…
Droguería Betances is a major wholesale drug distributor based in Puerto Rico that handles prescription products, consumer goods, OTC products and more. Hear from Frank Rivera, VP of Operations and…
Today marks the first birthday of LSPediA’s OneScan Verification Router Service (VRS) solution! Watch the video above to learn how our customers have benefited from partnering with LSPediA to take…
The US FDA published a compliance policy guidance document on September 23, 2019, announcing a one-year enforcement discretion for the Wholesale Distributor Verification Requirement for Saleable Returned Drug Product. Despite…
